Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Yosemite is a San Francisco-based venture capital firm founded in 2023, dedicated to addressing cancer with the goal of making it non-lethal within the lifetime of current generations. The firm operates at the intersection of for-profit investing and academic philanthropy, providing grants to support early cancer research while financing companies that translate oncology science into effective therapies and diagnostics. This dual approach allows Yosemite to improve patient experiences and advance the oncology ecosystem.
As of 2026, Yosemite has raised over $200 million for its second fund, targeting a total of $350 million. The firm has deployed more than $18 million in grants since its inception, demonstrating its commitment to funding both early-stage research and later-stage companies. Yosemite's office is located at 901 Battery St, San Francisco, CA 94111, and it operates globally, focusing on the United States and the broader oncology ecosystem.
Yosemite's investment strategy is centered on early-stage investments in oncology, specifically targeting seed and Series A funding for companies innovating in cancer therapeutics, diagnostics, and care delivery. The firm also provides grants for pre-commercial academic research, bridging the gap between high-risk academic work and conventional investment opportunities. This unique model allows Yosemite to support researchers and entrepreneurs across the oncology ecosystem, enhancing the development of therapies and improving patient care.
The firm seeks to invest in companies that are pioneering advancements in cancer treatment, diagnostics, and AI-enabled cancer care. Yosemite's check sizes are not publicly disclosed, but its focus on early-stage investments indicates a willingness to engage with startups at various stages of development. The firm values partnerships with both researchers and entrepreneurs, aiming to create a collaborative environment that fosters innovation in cancer treatment.
Yosemite has made significant investments in several notable companies within the oncology sector:
These investments reflect Yosemite's commitment to supporting innovative solutions in cancer treatment and care delivery, aligning with its mission to improve patient outcomes.
Reed Jobs: Founder and Managing Partner of Yosemite. Reed has a background in venture capital and previously worked with Emerson Collective before establishing Yosemite. He is known for his strategic insights into funding early cancer research and has been quoted regarding the firm's donor-advised fund strategy.
To pitch Yosemite, founders should send an email to info@yosemite.co. It is recommended to include a concise overview of the startup, its mission, and how it aligns with Yosemite's focus on oncology. Specific details about the pitch process, including response times and preferred formats, are not publicly disclosed.
In February 2026, PR Newswire reported that Yosemite had deployed more than $18 million in grants since its launch in 2023, highlighting the firm's commitment to supporting early cancer research. Additionally, VCWire reported in January 2026 that Yosemite had raised over $200 million toward its second fund, which targets a total of $350 million.
Yosemite's involvement in the oncology sector is further evidenced by its participation in Daymark Health's $20 million Series A funding round in September 2025, alongside other investors like Maverick Ventures and Oncology Ventures.
What are Yosemite's investment criteria?
Yosemite focuses on early-stage investments in oncology, specifically in cancer therapeutics, diagnostics, and care delivery. The firm looks for companies that are innovating in these areas and are at the seed or Series A funding stages.
How can I pitch to Yosemite?
Founders can reach out to Yosemite via email at info@yosemite.co. Specific details about the pitch process are not publicly disclosed, so it is advisable to provide a clear and concise overview of your startup and its alignment with Yosemite's focus on oncology.
What makes Yosemite different from other venture capital firms?
Yosemite uniquely combines venture capital with academic philanthropy, providing grants to support early cancer research while also investing in companies that translate scientific discoveries into market-ready solutions. This dual approach allows the firm to nurture early-stage research and facilitate the development of effective therapies.
What is Yosemite's geographic focus?
The firm operates globally, with a primary focus on the United States and the oncology ecosystem worldwide. This broad geographic scope allows Yosemite to partner with leading researchers and entrepreneurs across various regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, Yosemite's focus on early-stage investments suggests that it is prepared to engage with startups at various funding stages, including seed and Series A rounds.
What kind of support does Yosemite provide to its portfolio companies?
Yosemite adds value to its portfolio companies by combining financial support with strategic guidance, leveraging its network in the oncology ecosystem. The firm aims to facilitate the translation of scientific discoveries into effective therapies and improve patient experiences.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.